Fundraising Fox
Sinopia Biosciences
San Diego, US · Delaware corporation
Find your way into Sinopia Biosciences
Sign up to see every warm intro you have to Sinopia Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sinopia Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sinopia Bio is a biotechnology company developing a therapeutic pipeline focused on Parkinson's disease. It operates a drug discovery platform aimed at changing the trajectory of the disease.
Founders & leadership
AB
Aarash BordbarCo-FounderDr. Aarash Bordbar is co-founder and CEO/CSO of Sinopia Biosciences, which develops therapeutics for Parkinson's disease using a computational drug discovery platform. He holds a PhD from UC San Diego, has over a decade of experience in systems biology and bioinformatics, and has led NIH and Michael J. Fox Foundation-funded research since 2014.
BP
Bernhard PalssonNamed on SEC filing
IF
Iman FamiliNamed on SEC filing
Board
AT
Arthur T SuckowBoard director
Reported raises · per SEC filings
Form D private placements$2.8M disclosed across 1 round · 2026
▶$2.8MraisedJul 2026 · 35 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJul 2026 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aarash BordbarExecutive Officer, Director
- Arthur T SuckowDirector
- Bernhard PalssonDirector
- Iman FamiliDirector
- Offering amount
- $4.3M
- Amount sold
- $2.8M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $318.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $577.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $442.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $190.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $223.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Sinopia Biosciences do?
- Sinopia Bio is a biotechnology company developing a therapeutic pipeline focused on Parkinson's disease. It operates a drug discovery platform aimed at changing the trajectory of the disease.
- Who founded Sinopia Biosciences?
- Sinopia Biosciences was founded by Aarash Bordbar.
- How much funding has Sinopia Biosciences raised?
- Sinopia Biosciences has disclosed $2.8M raised across 1 round.
- Where is Sinopia Biosciences headquartered?
- Sinopia Biosciences is headquartered in San Diego, US.